Aardvark Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in San Diego, California and currently employs 31 full-time employees. The company went IPO on 2025-02-13. The firm targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. The company is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).
How did AARD's recent EPS compare to expectations?
The most recent EPS for Aardvark Therapeutics Inc is $-0.99, beating expectations of $-0.89.
How did Aardvark Therapeutics Inc AARD's revenue perform in the last quarter?
Aardvark Therapeutics Inc revenue for the last quarter is $-0.99
What is the revenue estimate for Aardvark Therapeutics Inc?
According to 12 of Wall street analyst, the revenue estimate of Aardvark Therapeutics Inc range from $0.0 to $0.0
What's the earning quality score for Aardvark Therapeutics Inc?
Aardvark Therapeutics Inc has a earning quality score of B+/56.66083. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Aardvark Therapeutics Inc report earnings?
Aardvark Therapeutics Inc next earnings report is expected in 2026-08-05
What are Aardvark Therapeutics Inc's expected earnings?
Aardvark Therapeutics Inc expected earnings is $0.0, according to wall-street analysts.
Did Aardvark Therapeutics Inc beat earnings expectations?
Aardvark Therapeutics Inc recent earnings of $0.0 does not beat expectations.